The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. by Wilson, Leslie et al.
UC Merced
UC Merced Previously Published Works
Title
The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in 
California.
Permalink
https://escholarship.org/uc/item/72j404r8
Journal
International journal of environmental research and public health, 16(7)
ISSN
1661-7827
Authors
Wilson, Leslie
Ting, Jie
Lin, Harold
et al.
Publication Date
2019-03-28
DOI
10.3390/ijerph16071113
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
International  Journal  of
Environmental Research
and Public Health
Article
The Rise of Valley Fever: Prevalence and Cost Burden
of Coccidioidomycosis Infection in California
Leslie Wilson 1,*, Jie Ting 1, Harold Lin 2, Rahil Shah 1, Michael MacLean 3,
Michael W. Peterson 4, Nathan Stockamp 4, Robert Libke 4 and Paul Brown 5
1 Department of Clinical Pharmacy, University of California, San Francisco, CA 94118, USA;
jie.tingjie@gmail.com (J.T.); rahil.shah@ucsf.edu (R.S.)
2 Kaiser Permanente Fresno, Fresno, CA 93720, USA; Harold.H.Lin@kp.org
3 Kings County Department of Public Health, Hanford, CA 93230, USA; maclean.mlm@gmail.com
4 Department of Medicine, University of California, San Francisco (UCSF), Fresno, CA 93701, USA;
mpeterson@fresno.ucsf.edu (M.W.P.); nstockamp@fresno.ucsf.edu (N.S.); rlibke@fresno.ucsf.edu (R.L.)
5 Department of Social Sciences, Humanities and Arts, University of California, Merced, CA 95343, USA;
pbrown3@ucmerced.edu
* Correspondence: leslie.wilson@ucsf.edu; Tel.: +1-415-990-1012
Received: 15 February 2019; Accepted: 25 March 2019; Published: 28 March 2019


Abstract: Coccidioidomycosis (CM) is a fungal infection endemic in the southwestern United States
(US). In California, CM incidence increased more than 213% (from 6.0/100,000 (2014) to 18.8/100,000
(2017)) and continues to increase as rates in the first half of 2018 are double that of 2017 during the
same period. This cost-of-illness study provides essential information to be used in health planning
and funding as CM infections continue to surge. We used a “bottom-up” approach to determine
lifetime costs of 2017 reported incident CM cases in California. We defined CM natural history and
used a societal approach to determine direct and discounted indirect costs using literature, national
datasets, and expert interviews. The total lifetime cost burden of CM cases reported in 2017 in
California is just under $700 million US dollars, with $429 million in direct costs and $271 million
in indirect costs. Per person direct costs were highest for disseminated disease ($1,023,730), while
per person direct costs were lowest for uncomplicated CM pneumonia ($22,039). Cost burden varied
by county. This is the first study to estimate total costs of CM, demonstrating its huge cost burden
for California.
Keywords: coccidioidomycosis; California; cost-of-illness; economic analysis; Valley fever; infection;
cost; prevalence
1. Introduction
Coccidioidomycosis (CM), also known as Valley fever (VF), is a fungal infection endemic in the
southwestern portion of the United States (US; especially California and Arizona), as well as in parts
of Central and South America [1,2]. CM infection is caused by inhalation of spores (arthroconidia) that
become airborne from soil disturbances in endemic areas [2,3]. In California, reported CM incidence
increased from 6.0/100,000 in 2014 to 18.8/100,000 in 2017, representing a >213% increase in the
number of cases. More so, incidence rates in the first half of 2018 are almost double compared to the
same time frame in 2017, showing a continual rise in infections [4]. The reasons for this are not well
established. Given the precipitous rise in the number of infections, the lifetime treatment of CM will
be an increasing cost burden to the state of California.
Our goal is to model CM and its complications and to estimate the average lifetime healthcare
utilization and cost (direct and indirect) associated with CM among incident CM cases in California in
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2017. The lifetime model of CM estimates that 60% of CM cases are asymptomatic, while the remaining
40% may experience a self-limiting respiratory illness, life-threatening pneumonia, meningeal infection,
or dissemination [5]. The more severe disease manifestations often require long-term use of antifungal
medications and incur significant healthcare utilization [6]. Costs include direct and indirect factors.
Direct costs of CM include those for diagnosis, initial and follow-up physician visits, treatment
procedures, hospitalizations, medication, and home or nursing home care. Indirect costs include days
of work lost, morbidity disability payments, and mortality costs.
To our knowledge, only two economic studies were published on CM: a cost-effectiveness study
of a potential CM vaccine, and total charges of CM-associated hospitalizations in California [7,8]. In our
study, we model and estimate total lifetime costs of CM and its health consequences in California. Data
from our study can help policy-makers understand the importance of CM, recognize areas of healthcare
most affected by CM, and prioritize allocation of resources for treatment and prevention policies.
2. Materials and Methods
This cost-of-illness study used a “bottom-up” approach to estimate the lifetime costs of all 2017
reported incident cases in California. We firstly modeled the natural history of the disease, and then
calculated lifetime costs by identifying specific items of healthcare use. The frequency of healthcare
use was then multiplied by the proportion of cases utilizing the item of healthcare, and the costs of
each item. We used a societal approach and determined both direct and indirect costs in 2017 US
dollars and discounted lifetime indirect costs to present value. Our data were obtained from literature,
national datasets, and expert interviews (Drs. Harold Lin, Michael MacLean, Michael Peterson, Nathan
Stockamp, Robert Libke, personal communication, January–August 2014), and was exempted by
the University of California, San Francisco (UCSF) Institutional Review Board. Expert interviews
were used to better understand the natural progression of valley fever and helped guide treatment
algorithms. A literature-based initial lifetime treatment model was modified by each expert based on
their clinical experience (see Figure S1, Supplementary Materials). Experts each estimated population
probabilities at each point in the model based on their extensive experience and knowledge treating
coccidioidomycosis infections, especially in endemic areas of California. Any differences among
experts were then discussed, and a consensus was reached on the best estimates before national costs
were applied. These methods are used frequently, in cases such as these, to supplement estimates
where literature and databases lack the necessary detailed information [9].
2.1. Study Population
Our study population was 2017 reported CM cases in California (n = 7466) (the latest data
available). We estimated the expected lifetime cost of CM for our study population based on the
natural history of CM and its published treatment guidelines (Table 1). To address the gap in literature
on the healthcare utilizations of CM patients and expected loss in productivity from the disease,
we conducted guided interviews with CM treatment experts from endemic settings in California.
The guided interviews were one to two hours of discussion with each expert separately using a
literature-based, itemized spreadsheet of disease epidemiology, natural history, diagnosis, treatment,
and follow-up. Experts were asked questions regarding exact population probabilities at each point
of the natural history disease model. Healthcare utilization of the pre-determined treatment options
derived from literature review were also estimated based on their treatment experience and records.
To construct a natural history model for the disease, we firstly identified the major manifestations
of CM from the literature and expert opinion: (1) uncomplicated pneumonia, (2) diffuse and/or chronic
pneumonia with no dissemination, (3) disseminated disease, including meningitis, and (4) other
changes in chest, including chronic pulmonary nodules, and chronic pulmonary cavity. We determined
the proportion of patients experiencing each CM manifestation.
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Table 1. Estimated direct lifetime costs per person, stratified by types of costs and coccidioidomycosis (CM) disease manifestation in California.
Cost Type Item Utilization Average Per PersonLifetime Cost 1 Reference
Uncomplicated pneumonia
Pre-CM diagnosis 2
Physician visit 100% had 3 physician visits $487
[10] 3ER visit 23% first sought care in ER $17
Medication Azithromycin/levaquin 100% (50% will require 2nd course) $114
Diagnosis Immunodiffusion and titer 100% (25% will require repeat testing)
$322 [11] 3
Chest X-ray 100%
Chest CT 25%
Others, HIV testing 100%
Post-CM diagnosis
Hospitalization Requiring hospitalization 40%
$13,027 3
1 lifetime hospitalization 90%
2 lifetime hospitalizations 7%
>2 lifetime hospitalizations 3%
Medication Fluconazole (400 mg/day) 90% (6 months)
$6891 [12] 3
Itraconazole (200 mg twice/day) 3% (6 months)
Amphotericin B (3 mg/kg/day) 2% (for pregnant women, 6 months)
Voriconazole (200mg twice/day) 5% (after failing fluconazole/voriconazole, 6 months)
Follow-up Immunodiffusion and titer 100% every 3 months for 12 months (expected
compliance 50–80%) $1181
3
Chest x-ray
Home care/nursing home None $0 Assumption 3
Total $22,039
Diffuse/chronic pneumonia without
dissemination
Pre-CM diagnosis Same as for CM-associated uncomplicated pneumonia $618
[10] 3Other medication 4-drug regimen for tuberculosis 10% (1 month) $17
Diagnosis Immunodiffusion and titer 100% (25% will require repeat testing)
$321 [11] 3Chest X-ray 50% have 2 X-rays/year outside of hospital
Chest CT 30% have chest CT outside of hospital
Post-CM diagnosis
Hospitalization 1st hospitalization in year 1 75%
$68,532 32nd hospitalization in year 1 65% (of those with 1st hospitalization)
Hospitalization in year 2 100%
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Table 1. Cont.
Cost Type Item Utilization Average Per PersonLifetime Cost 1 Reference
Medication Fluconazole (400 mg/day) 75% (36 months)
$55,313 [12] 3Itraconazole (200 mg twice/day) 25% (36 months)
Follow-up Immunodiffusion and titer 100% every 3 months for 12 months (expected
compliance 50–80%) $1566 3Chest X-ray
Chest CT 100% (at discharge, expected compliance 50–80%)
Home care 100% (3 days a week for 3 months) $2450
Assumption 3Rehabilitation facility 100% (30 days) $3599
Total $132,416
Dissemination, including meningitis
Pre-CM diagnosis Same as for CM-associated uncomplicated pneumonia.40% first sought care in ER $618 [10]
3
Diagnosis
Immunodiffusion/titer/chest
X-ray/chest CT
Same as for CM-associated diffuse/chronic pneumonia
without dissemination
$737 [11] 3
Lumbar puncture 50%
MRI 15–20%
Aspirates of joint effusions 10%
Skin biopsy 10%
Bone marrow biopsy 5%
Lung biopsy 20%
Lymph node biopsy 20%
Liver biopsy 5%
Post-CM diagnosis
Hospitalization 1st hospitalization in year 1 100%
$672,730 32nd hospitalization in year 1 65% (of those with 1st hospitalization)
Hospitalization after year 1 100% hospitalized once a year for life
Medication Fluconazole (1,000 mg/day) 98% (lifelong)
$321,899 [12] 3Amphotericin B (3 mg/kg/day) 2% (lifelong)
Other treatment considerations
Ventriculoperitoneal shunt placement 15% of those with meningitis
$7691 [12] 3Ventriculoperitoneal shunt replacement 100% of shunts replaced once in lifetime
Follow-up Immunodiffusion and titer
100% (every 3 months in year 1, every 6 months for life;
MRI every 6 months for life; lumbar puncture 2 times in
year 1, 5 times in lifetime; expected compliance 50–80%)
$16,877 3
Chest X-ray
Chest CT
Liver function test
Renal function test
MRI
Lumbar puncture
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Table 1. Cont.
Cost Type Item Utilization Average Per PersonLifetime Cost 1 Reference
Home care 100% (3 days a week for 3 months) $2450
Assumption 3Nursing home Temporary stay 10% (2 months) $728
Total $1,023,730
Other changes in chest, pulmonary
nodule
Pre-CM diagnosis Same as for CM-associated uncomplicated pneumonia $618 [10] 3
Diagnosis Immunodiffusion and titer 100% (25% will require repeat testing)
$76,631 [11,13] 3
Chest X-ray 100%
Chest CT 25%
Diagnostic work-up for lung cancer (CT
scan, biopsy if indeterminate, watch and
wait if benign)
90%
Post-CM diagnosis
Hospitalization Same as for CM-associated uncomplicated pneumonia $13,027 3
Medication Requiring medication 25%
$1561 [12] 3
Fluconazole (400 mg/day) 90% (6 months)
Itraconazole (200 mg twice/day) 5% (6 months)
Voriconazole (200 mg twice/day) 5% (after failing fluconazole/voriconazole, 6 months)
Follow-up Immunodiffusion and titer 100% every 3 months for 12 months, then every 6months for 1 year (expected compliance 50–80%) $3562
3
Chest X-ray
Home care/nursing home None $0 Assumption 3
Total $95,399
Other changes in chest, pulmonary
cavity
Pre-CM diagnosis
Same as for CM-associated changes pulmonary nodule $95,399 [10,11] 3Diagnosis
Post-CM diagnosis
Additional hospitalization
Cavity complications 5% $4207 3
Hemoptysis/chest pain 5–10% $2142 3
Home care/nursing home None $0 Assumption 3
Total $101,748
CT = computerized tomography; HIV = human immunodeficiency virus; MRI = magnetic resonance imaging; ER = emergency room. 1 Drug costs were from Red Book Online (Truven
Health Analytics); medical procedure costs from Centers for Medicare and Medicaid Services CPT (Current Procedural Terminology) codes. 2 Applies to all CM disease manifestations. 3
Harold Lin, Michael MacLean, Michael Peterson, Robert Libke, Nathan Stockamp, personal communication.
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Our natural history model (Figure 1) has several analytic assumptions. We assumed that 60%
of annual CM cases are asymptomatic and, therefore, not reported. All asymptomatic cases were
assumed to recover and develop immunity against CM and, therefore, did not seek healthcare nor
incur any cost. Secondly, it is assumed that the annual reported cases represent the remaining 40% with
symptoms of varying degrees, consistent with literature [5,6]. Finally, patients with CM misclassified
as community-acquired pneumonia were included in the healthcare and diagnosis and treatment costs
incurred before correct CM diagnosis [14–16].
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Figure 1. occidioidomycosis natural history. CAP = co munity-acquired pneumonia; spp = forma
specialis.
is shows the natural history of Coccidio omycosis based on published literature [2,4,5,14],
treatment guidelines [12], and expert interviews (Harold Lin, Michael acL an, Michael Peterson,
Robert Libke, Nathan Stockamp, personal communication, January–August 2014).
Among the symptomatic cases, ~85–90% will have uncomplicated, self-limiting pneumonia, ~2.5%
will have diffuse or chronic pneumonia without dissemination, and ~2.5% will have disseminated
disease, including meningitis, while the remaining ~10% will have other chest changes (70% chronic
pulmonary nodule, 30% chronic pulmonary cavity). Among those with diffuse/chronic pneumonia
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without dissemination, 5–10% will die in the first 2–3 years of having CM, while the remaining were
assumed to have mortality rates consistent with mild chronic obstructive pulmonary disease. Among
those with dissemination, including meningitis, 30% will die in the first five years of having CM,
while the remaining will have, on average, 5–10 years of life lost. Among those with other changes in
the chest, 1–2% will die in the first five years, while the remaining will have normal life expectancy.
Lifetime burden of disease was calculated using an average disease onset at 46 years of age and an
average life expectancy with a CM infection of 60 years [6].
2.2. Costs
We included both direct and indirect costs. Direct-care costs were those related to diagnosis,
treatment, and follow-up of CM. Indirect costs were related to productivity losses due to CM.
Categories of direct costs included diagnosis and treatment for respiratory symptoms before CM
diagnosis (“pre-CM diagnosis”), CM diagnosis, initial and follow-up physician visits, treatments,
procedures, hospitalizations, medications, and home or nursing home care. Data on CM-associated
hospitalizations was obtained from the California patient discharge dataset 2017 using ICD-10
B.38.0-B.38.4, B38.89, and B38.9. Per person lifetime costs were the sum of lifetime direct and indirect
costs. Total lifetime cost for California was calculated by multiplying the number of patients in each
disease manifestation by their respective per person lifetime costs.
National costs sources included the Centers for Medicare and Medicaid Services CPT (Current
Procedural Terminology) codes for costs of diagnosis, physician visits, and treatment procedures,
the average wholesale price (AWP) of 17% for contract pricing using Red Book Online (Truven Health
Analytics) for medication costs, and the Healthcare Cost and Utilization Project (HCUP) for national
hospitalization costs by ICD-10 codes for CM [17,18]. Home-care costs were obtained from the US
Bureau of Labor and Statistics (BLS), and nursing home costs were obtained from the US Department
of Health and Human Services [19]. Indirect costs were salaries and compensation from the Bureau of
Labor Statistics [20].
Indirect costs included work loss, short- and long-term disability, and mortality costs. The human
capital approach was used to value lifetime productivity losses due to work loss and mortality.
Estimates from Federal Reserve Economic Data were used to determine the average annual hours
worked (1758), multiplied by average hourly compensation, wages, and salary ($32) for each day
lost on an annual basis ($56,798 from 2012 to $59,214 in 2016) [21,22]. Compensation was increased
annually to reflect projected increases to wages and salaries (1.6%) and to compensation (2.1%) until
2014. From 2015 to 2020, we increased compensation, wages, and salary by 1.55% per year, based
on BLS projections. From 2020 to 2024, we estimated a 2% increase based on assumed easing of the
economic downturn by then. An annual unemployment rate from 2012 to 2016 (10.4 to 8.0%), 8%
until 2019, and 7% after 2020 was used to decrease the proportion with productivity losses, and as the
economy is expected to improve slowly over time. Disability payments included the average short-term
disability payments for California in 2016, an average of $488/week for 16 weeks [23]. Long-term
disability payments included Supplemental Security Income (SSI) for those with disseminated disease.
We assumed long-term disability was received for 10 years, and discounted these payments by the
current discount rate (1%) [24]. Average SSI payments included both Federal and State payments for
2016 ($552/month) and, beyond that, they were increased annually by 1.4%.
Final cost burden was the total of all direct and indirect lifetime costs per reported CM case and
across all reported cases in California. The base case indirect cost estimates were inflated for increases
in healthcare costs and discounted to present dollars. Direct costs were not discounted because most
costs occur in the first two years. Direct costs beyond the first year (e.g., hospitalizations) were also not
discounted as these were estimated to occur during a person’s lifetime, but were not attributable to an
exact future year.
Multiple one-way sensitivity analyses were also conducted. Ranges of ±10% were used to vary
the percentage of individuals that were shown to be symptomatic and, thus, an incident case, as these
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cases may be under- or over-reported. Also, the number of individuals in each disease manifestation
was adjusted to reflect any potential errors in reporting or misdiagnosis. Lastly, medication costs were
identified as a major source of cost burden, especially for those who had disseminated disease and,
therefore, were subject to sensitivity analysis by varying their costs by ±25% of the base case.
3. Results
The estimated total lifetime cost burden of all the CM cases reported in 2017 (n = 7466) in California
is just under $700 million (discounted), with $429 million in direct costs and $271 million in indirect
costs (Table 2).
Table 2. Estimated total direct and indirect lifetime costs, stratified by types of costs and coccidioidomycosis
(CM) disease manifestation, for incident CM cases in 2017 (n = 7466) in California.
CM Disease Manifestation Number(n = 7466)
Average Per Person
Lifetime Cost
Total Lifetime Cost
for California
Direct costs
Uncomplicated pneumonia 6346 $22,039 $139,859,494
Diffuse/chronic pneumonia without dissemination 187 $132,416 $24,761,792
Dissemination, including meningitis 187 $1,023,730 $191,437,510
Other changes in chest, pulmonary nodules 522 $95,399 $49,798,278
Other changes in chest, pulmonary cavity 224 $101,748 $22,791,552
Indirect costs
Uncomplicated pneumonia 6346 $931 $5,908,126
Diffuse/chronic pneumonia without dissemination 187 $350,063 $65,461,781
Dissemination, including meningitis 187 $562,291 $105,148,417
Other changes in chest, pulmonary nodules 522 $126,883 $66,232,926
Other changes in chest, pulmonary cavity 224 $126,883 $28,421,792
Total costs of CM
Direct costs $428,648,626
Indirect costs $271,173,042
Work loss $11,825,936
Disability $4,156,449
Mortality $255,190,657
Total direct + indirect costs $699,821,668
3.1. Direct Costs
The average lifetime direct costs per person across all manifestations of CM are high ($57,413).
Accounting for the frequency of each manifestation of the disease, CM with dissemination, including
meningitis, still accounts for the highest total direct costs (over $191 million), followed by those with
CM-associated uncomplicated pneumonia (85% of reported cases), which cost almost $140 million.
The other CM manifestations contributed less to the overall total California costs.
3.1.1. Uncomplicated Pneumonia
CM-associated uncomplicated pneumonia incurred the lowest per person lifetime direct costs
($22,039) among all CM disease manifestations (Table 2). This included a pre-CM diagnosis period
with an estimated three physician visits and a course of antibiotics. We also assumed 50% of these
pre-CM diagnosis cases had a second course of antibiotics, and that 23% firstly sought healthcare in the
emergency department (ED) [10]. The initial diagnosis of CM consisted of an immunodiffusion (ID)
serologic test and complement fixation (CF) titer, plus a chest X-ray for all patients with uncomplicated
pneumonia. An estimated 25% of patients would require a second ID and CF titer, as well as a
chest computerized tomography (CT). The largest areas of cost for CM-associated uncomplicated
pneumonia were hospitalizations ($13,027) and medications ($6891). We estimated 70% would not
require hospitalization, while the remaining 30% would require hospitalization at least once, with
fewer patients needing more than one hospitalization due to CM in their lifetime. Fluconazole is
the preferred treatment for all CM cases, but the dose and length of treatment varied by type of
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disease manifestation. Other antifungals used included itraconazole, amphotericin B (primarily in
pregnancy or severe CM cases), and voriconazole, if failing fluconazole treatment. In uncomplicated
pneumonia, antifungal treatment lasted six months and lifetime medication costs were $6891 per
person. We assumed a regime for follow-up costs which primarily included repeat ID testing and titers
and chest X-rays, which varied by disease group.
3.1.2. Diffuse/Chronic Pneumonia
CM-associated diffuse/chronic pneumonia without dissemination is much more costly per person
than uncomplicated pneumonia, primarily due to increased risks of hospitalization over their lifetime,
and longer use of antifungals (average, 36 months). Follow-up testing is also more intense with
CM-associated chronic/diffuse pneumonia. Physicians interviewed suggested they ideally follow the
disease progression with ID and titers and chest X-rays at three-month intervals for the first 12 months,
but that (many) patients do not fully comply with this recommendation. Therefore, we also accounted
for the expected loss to follow-up in our costing (Table 2). Total lifetime per person direct costs for
CM-associated diffuse/chronic pneumonia without dissemination are about $132,000, five times higher
than for CM-associated uncomplicated pneumonia.
3.1.3. Disseminated Disease, Including Meningitis
CM infections can sometimes lead to severe disseminated disease (~1% of total CM infections) [5].
Lifetime direct costs per person of CM-associated dissemination, including meningitis, were $1,023,730,
almost eight times as high as for CM-associated pneumonia without dissemination. Here, diagnosis
confers a greater morbidity and is more costly as more organs can be affected, including the skin,
bones, joints, and the central nervous system (CNS). Estimated lifetime hospitalization costs were
especially high for these patients ($672,730). Additionally, those with disseminated disease require
lifelong antifungals, totaling $321,899 per person.
Also contributing to the high costs of CM-associated dissemination, including meningitis, is the
use and revision of ventriculoperitoneal shunts. Patients with CNS infections or coccidioidal meningitis
are at risk of complications including hydrocephalus. Shunts are used therapeutically to relieve
hydrocephalus that occurs in approximately 30–50% of coccidioidal meningitis [25]. In some cases,
shunts may be used for administration of medication. These types of shunts commonly fail, and many
patients require one or more surgical revisions [26].
Finally, additional costs were accrued due to frequent follow-up testing, as well as requirements
for temporary home care and short- and long-term nursing home placement for a small proportion
of individuals with disseminated disease. This results in average lifetime per person costs of over
$1 million ($1,023,730), quite a significant burden for an individual.
3.1.4. Pulmonary Nodules or Cavities
The estimated direct costs for treating individuals with CM-associated pulmonary nodules or
cavities were surprisingly high. These patients are sometimes diagnosed with CM only when a nodule
is found on a chest X-ray done for another medical reason. This results in the need to conduct a
diagnostic lung cancer work-up to rule out lung cancer in 90% of these individuals, as indicated by
expert opinions. This work-up is costly (~$76,000), and may be an area for cost savings if characteristics
of the nodule or cavity can be better targeted to CM rather than cancer. The total estimated lifetime per
person direct costs for CM with pulmonary nodule are $95,399, and they are slightly higher with a
pulmonary cavity ($101,748) because of additional bleeding complications from cavity ruptures.
3.2. Indirect Costs
Estimated total indirect costs included work loss, short-term and long-term disability payments,
and productivity losses due to mortality (Table 3).
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Table 3. Estimated indirect lifetime costs per person, stratified by types of costs and coccidioidomycosis (CM) disease manifestation in California.
Cost Type Frequency and Utilization Average Per Person Lifetime Cost 1 Reference
Uncomplicated pneumonia
Work loss 7 days $931 [10] 5
Disability None $0 5
Mortality Normal life expectancy $0
Total $931
Diffuse/chronic pneumonia without
dissemination
Work loss 90 days $11,971 [10] 5
Disability 16 weeks short-term CA disability $7804
5Mortality 2 5–10% death in first 2–3 years
$330,288 3Remainder have mortality rates consistent with mild COPD
(4.3% annually)
Total $350,063
Dissemination, including meningitis
Work loss 120 days $15,961 [10] 5
Disability 16 weeks short-term CA disability $7804
5Long-term social security payment
$6619 3,4State payments for those with permanent disability
Mortality 2 30% death in first 5 years.
$531,907 3
5
Remainder have mortality rates consistent with twice that
of mild COPD (8.6% annually) [27]
5
Total $562,291
Other changes in chest, pulmonary nodule
Work loss 7 days $931
5Disability None $0
Mortality 2
1% death in first 5 years. Remainder have normal life
expectancy $125,952
Total $126,883
Other changes in chest, pulmonary cavity
Work loss 7 days $931
5Disability None $0
Mortality 1% death in first 5 years. Remainder have normal lifeexpectancy $125,952
Total $126,883
COPD = chronic obstructive pulmonary disease; CA = California. 1 Drug costs were from Red Book Online (Truven Health Analytics); medical procedures costs from Centers for Medicare
and Medicaid Services CPT codes. 2 We assumed all deaths have an average 10 years of life lost. 3 Discounted at 1% per year. 4 Average payment increase of 1.4% per year. 5 Harold Lin,
Michael MacLean, Michael Peterson, Robert Libke, Nathan Stockamp, personal communication.
Int. J. Environ. Res. Public Health 2019, 16, 1113 11 of 16
3.2.1. Early Work Loss
We estimated an average total work loss of seven days for CM-associated uncomplicated pneumonia,
and for CM-associated pulmonary nodules and cavities, while an estimate of 43 days of work loss was
obtained among CM-associated diffuse/chronic pneumonia patients without dissemination. Among
CM-associated dissemination, we estimated 10% had permanent work loss, and the remaining 90% had
an average work loss of 90 days. Work-loss costs were lowest for those with uncomplicated pneumonia,
and those with nodules or cavity ($931), and highest for those with diffuse/chronic pneumonia and
those with dissemination ($11,971–$15,961).
3.2.2. Disability
Those with diffuse/chronic pneumonia had an average estimated 16 weeks of short-term California
disability payments, and 10% of those with dissemination had 10 years of long-term disability
payments. This resulted in total disability payments across all CM patients of $4,156,447 (discounted),
of which more than half were for those few patients with disseminated disease ($2,697,101).
3.2.3. Mortality
Mortality and life expectancy were estimated by disease manifestation group. We assumed
a normal life expectancy for those with CM-associated uncomplicated pneumonia, resulting in no
productivity losses due to mortality. Among those with CM-associated diffuse/chronic pneumonia
without dissemination, mortality was estimated to be 5–10% per year for the first three years, while the
remainder (90–95%) had a mortality rate consistent with mild chronic obstructive pulmonary disease
(COPD) (35% in 10 years, ~4.3% per year) [27]. We estimated the mortality of those with disseminated
disease at 30% per year for the first five years and then had twice the mortality rate of mild COPD
(~8.6% per year) for the next five years. Again, mortality wage loss costs were estimated to account for
10 years of additional life expectancy lost compared to normal life expectancy. These lost productivity
wages were increased for wage inflation and discounted for net present value estimates. Mortality for
those with pulmonary nodules and cavities was 1% per year in the first five years with 10 years of lost
productivity for those dying. Those not dying in the first five years were assumed to have a normal
life expectancy.
Estimated total lifetime mortality costs were highest for those with disseminated CM ($531,907).
Those with nodules or cavities, diffuse/chronic pneumonia without dissemination, and those with
dissemination, including meningitis, had mortality costs ranging from $125,952–$531,907.
3.2.4. Costs by County
We estimated cost burden by county by calculating total CM costs in endemic counties (Fresno,
Kern, Kings, Madera, San Luis Obispo, and Tulare), as well as those with >100 reported CM cases in
2017 (Table 4) [4,8]. Cost burden ranged from $6.0–$13.3 million for the two counties with the lowest
cost, to $87.5–$257.5 million for the two counties with the highest cost burden. Three other counties,
although not classified as endemic, also had a high cost burden: Los Angeles ($87.5 million), San Diego
($13.3 million), and Monterey county ($17.1 million). Madera, although endemic, had the lowest costs
of this group ($6.1 million).
In sensitivity analyses, the percentage of individuals that were classified under each disease
manifestation was varied by a 10% range above and below the total number of individuals that
were reported to have CM in California in 2017. From an estimated base of 60% of CM cases being
asymptomatic, and again varying by 10% above and below this rate, the total direct and indirect
lifetime costs to California can span from $874 million to $524 million. We also adjusted by 10% the
percentage of CM cases presenting as uncomplicated pneumonia. This variation from 76.5–93.5% gave
a range of total lifetime costs to California from $314 million to $1.1 billion.
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Medication costs in our base case estimates were also a significant source of cost burden in the
treatment of CM. Varying lifelong medication costs for those who have disseminated disease ±25%
changed the total lifetime direct and indirect costs of CM in California from $720 million to $690 million.
Table 4. Estimated total direct and indirect lifetime costs, stratified by endemic counties and counties
with >100 reported coccidioidomycosis (CM) cases in 2017 in California.
County Number (n = 7466) Direct Cost Indirect Cost Total Cost
Fresno * 824 $47,308,662 $29,928,554 $77,237,216
Kern * 2748 $157,772,090 $99,810,276 $257,582,366
Kings * 260 $14,927,490 $9,443,476 $24,370,966
Los Angeles County 934 $53,624,138 $33,923,871 $87,548,009
Madera * 65 $3,731,873 $2,360,869 $6,092,742
Monterey 182 $10,449,243 $6,610,433 $17,059,676
San Diego 142 $8,152,706 $5,157,591 $13,310,297
San Luis Obispo * 419 $24,056,225 $15,218,525 $39,274,749
Tulare * 275 $15,778,692 $9,988,292 $25,776,983
* Coccidioidomycosis endemic counties.
4. Discussion
The estimated total cost burden of CM in California is high, with about $429 million in direct
and $271 million in indirect costs for the lifetime of cases reported each year. Direct costs are higher
than the indirect costs, accounting for about 61% of total costs. The large indirect cost burden rests
primarily on a small number of cases with disseminated disease, although those with chronic/diffuse
pneumonia without dissemination also share in this indirect cost burden.
Lifetime per person costs of CM in California were $94,000, with $58,000 direct and $36,000
indirect costs. With the recent annual increase in number of new cases in California, the total costs
likely will increase over time. For example, reported incidence from January through July 2018 showed
an increase of almost 75% compared to the same months in 2017, although reported cases are lower
again in August of 2018 [4]. The CM cost burden is not shared equally among California counties.
Although the defined endemic counties generally experience the highest cost burden, this is not always
the case. For example, Madera County (defined as endemic) has a small population and small cost
burden, while three non-endemic counties have relatively high cost burdens. Patients with CM who
are uninsured will need to rely on county or hospital funds for their care. The county-specific CM cost
burden should be considered when estimating healthcare budgets in these counties.
The economic burden of CM is greater than many other region-specific diseases. For example,
estimated lifetime direct per person costs of Chagas disease (a parasitic disease found in southern
regions of United States and Latin America) was only $29,111, about half the costs of CM [28].
Lyme disease has a direct annual per person cost of $3953 (2017 dollars), with an estimated total
annual cost of $3.2 billion [29]. The average per person costs of treating multidrug-resistant TB
(MDR-TB) is $140,000, increasing to $452,000 for extensively drug-resistant TB, only about half of
the direct costs of CM treatment [30]. However, adding productivity losses to treatment costs for
MDR-TB brings the estimated cost per case to $583,000, which is much higher than the $94,000 per
person total direct and indirect costs of CM. Lifetime total costs of care per human immunodeficiency
virus (HIV)-infected patient ($400,000) is also higher than for CM, although costs per breast cancer
patient ($21,000–$105,000) is more similar to CM [31,32]. Although differing methodologies to calculate
costs were used in these studies, these comparisons in understanding the overall cost burden of CM
remain relevant.
Average CM total lifetime costs and per person lifetime costs are high ($700 million and $94,000,
respectively). Disseminated cases, including meningitis, incur the highest cost due to long-term
treatment needs. Cancer work-up for nodules and cavities offers an opportunity for cost control.
Decreasing the cost of the 90% of patients receiving a complete cancer work-up by half could save
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almost $38,000 per person in this CM group ($196,000 to $120,000). This could also reduce the total
California lifetime CM costs by $28 million ($700–$672 million). The direct cost of treatment is 61% of
total costs, likely due to the high cost of repeat hospitalizations and antifungal treatment over many
years. Indirect costs are also high and may be underestimated given the lack of strong mortality and
life expectancy data for CM cases. The availability of more accurate data on mortality would improve
these estimates. The disseminated cases, although rare, account for much of the direct and indirect
costs, given their long treatment needs and higher mortality and disability. Uncomplicated pneumonia
cases account for a high proportion of the direct costs as well, due to their high volume compared to
the other groups.
It is important to note that our experts expressed that CM cases are a diverse group of patients,
with a large variation in utilization and costs by geographic region, as well as in their availability
of insurance and, therefore, access to care. They describe that there are many cases of CM in
undocumented workers who are not currently insured, and who are receiving care from state-run
clinics or accessing free care. They also indicated that these workers are less likely to seek care or
follow-up on their recommended treatment over time. It is important to examine some of these
variations in population type and subsequent care in future studies.
Our study has a few limitations. Firstly, we assumed that all symptomatic cases and, therefore,
those who incurred costs were reported. While symptomatic cases could remain misclassified
as community-acquired pneumonia, some reported cases may also be asymptomatic or are false
positives [14–16]. More accurate estimation on the number of symptomatic cases among the reported
cases is needed in California. Secondly, we estimated that 2.5% of our population have dissemination,
including meningitis, consistent with literature [5,33]. However, a recent study reported that up to
8% of CM infections could progress to disseminated disease [34]. This would substantially increase
the total lifetime cost of disseminated disease. More accurate estimation of the risk of dissemination
is, therefore, needed. Thirdly, our experts expressed that there was considerable variation in the use
of shunts. We estimated that 15% of those with meningitis would require shunt placement to relieve
hydrocephalus. Although hydrocephalus occurs in 30–50% of coccidioidal meningitis, we are unsure
how many would require or receive a shunt [25]. Although the estimated lifetime cost per person
of shunt placement/replacement in our population is low (<$8000), the cost of shunt placement to a
patient requiring the procedure, including hospitalization, is high (~$52,000). It is, therefore, important
to be able to more accurately estimate the frequency and value of shunt placement. Additionally,
as information regarding medical services provided was partly obtained through expert interviews, this
method may skew cost calculation based on a practitioner’s opinion. However, expert panel interviews
were shown to be useful in previous cost-of-illness studies for diseases with undefined treatment
pathways when this is the best available evidence source, especially for outpatient expenses [35,36].
As our study is the first to calculate the total lifetime cost of CM in California, it may be used as a
stepping stone for additional studies which should incorporate the use of medical claims data. Claims
data are limited for calculation of lifetime costs for this disease, however, since many cases present
only as uncomplicated pneumonia. Finally, there is some debate about the helpfulness of cost-of-illness
studies to bring about policy change toward a specific disease. Other economic methods such as
cost-effectiveness analyses can also be helpful, but focus more on comparing the economic value of
different treatment approaches. Cost-of-illness studies can provide a detailed overview of the factors
that contribute toward a disease and its progression, as well as the associated costs. Our cost-of-illness
study can inform later cost-effectiveness studies and can allow for potential interventions to be tested
and prioritized given the disease specific data obtained from the research. Cost-of-illness studies may
also provide a better estimation of population health and allow for insight into potential health gaps
for a certain disease [37,38].
Future studies can examine costs in more depth, using utilization and cost data from larger
databases in California, to provide more assurance of the accuracy of our cost estimates. Future studies
should also include the rapid diagnostic test (by DxNA) approved in December 2017 with the potential
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to shorten testing times, and allow preventative testing of those going into high risk areas. If rapid
testing for antibodies prior to starting work in high risk areas was the standard, appropriate risk
mitigation strategies (NIOSH-certified breathing mask or relocation) could be taken to reduce the
chance of a CM infection in those at highest risk [39–41].
5. Conclusions
The National Institute of Health, Institute of Medicine, and the US Congress recognize the importance
of cost-of-illness studies in setting research priorities [42]. This cost-of-illness study can help define
the magnitude of the disease in dollars, and provide an important guide and resource justification
for policy development, priority setting, and management of public health. As coccidioidomycosis
infections continued to rise in California in the first half of 2018, our detailed analysis defining its
high economic impact gains enhanced relevance. This study models the natural history of Valley
fever, detailing the specific areas of highest cost burden, and providing cost estimates for the first
time. Future economic research will need to address the high potential to reduce overall healthcare
expenditure, with adoption of the newly available diagnostic measures and enhanced mitigation
strategies for those at most risk in endemic areas of California.
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